Open AccessThis article is
- freely available
Role and Redirection of IgE against Cancer
Molecular Immunology Group, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
Protein Engineering and Therapeutics Group, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
* Author to whom correspondence should be addressed.
Received: 4 April 2013; in revised form: 13 May 2013 / Accepted: 14 May 2013 / Published: 28 May 2013
Abstract: IgE is a highly elusive antibody class, yet a tremendously powerful elicitor of immune reactions. Despite huge efforts spent on the characterization and understanding of the IgE system many questions remain either unanswered or only marginally addressed. One above all relates to the role of IgE. A common doubt is based on whether IgE mode of action should only be relegated to anti-parasite immunity and allergic manifestations. In search for a hidden role of IgE, reports from several laboratories are described herein in which a natural IgE link to cancer or the experimental redirection of IgE against cancer have been investigated. Epidemiological and investigational studies are trying to elucidate a possible direct intervention of endogenous IgE against cancer, raising thus far no definitive evidence. Conversely, experimental approaches implementing several strategies and engineered IgE formats built up a series of convincing results indicating that cancer might be tackled by the effector functions of this immunoglobulin class. Because of its peculiar immune features, IgE may present a superior anti-tumor performance as compared to IgG. However, extreme care should be taken on how IgE-based anti-tumor approaches should be devised. Overall, IgE appears as a promising resource, likely destined to enrich the anti-cancer arsenal.
Keywords: IgE; FceRI; CD23; ADCC; cancer; immunotherapy
Citations to this Article
Cite This Article
MDPI and ACS Style
Nigro, E.A.; Siccardi, A.G.; Vangelista, L. Role and Redirection of IgE against Cancer. Antibodies 2013, 2, 371-391.
Nigro EA, Siccardi AG, Vangelista L. Role and Redirection of IgE against Cancer. Antibodies. 2013; 2(2):371-391.
Nigro, Elisa A.; Siccardi, Antonio G.; Vangelista, Luca. 2013. "Role and Redirection of IgE against Cancer." Antibodies 2, no. 2: 371-391.